Flexible administration Options.1
HYQVIA offers flexible administration options. Healthcare professionals can work with their patients to determine:
- Either 1 or 2 infusion sites (A second site can be used at the discretion of the physician and patient based on tolerability and total volume.)
- Infusion site location in either the abdomen or the thighs
- Every 3 or 4-week treatment intervals
- Infuse at home or in-center
Continue Reviewing Safety Information
Review Important Safety Information, including contraindications and specific warnings and precautions to take when prescribing and monitoring patients treated with HyQvia.
Start with the right equipment
The Specialty Pharmacy will send out infusion equipment for infusing HYQVIA.
Below are some guidelines that may be helpful to understand.
Selecting infusion equipment
Select a pump for administering HYQVIA that is1:
- Indicated for subcutaneous use
- Capable of infusing a patient's dose at infusion rates up to 300 mL/h/site
- Able to titrate the flow rate up or down while part of a fully assembled administration system
- Able to be set with maximum occlusion alarm setting at least 11.6 psi1
Select a subcutaneous needle set for administering HYQVIA that1:
- Is 24 gauge and labeled for high flow rates (or low resistance)
- Is either single or bifurcated, depending upon number of infusion sites
- Has a needle positioned at a 90-degree angle
Potential additional equipment for administering HYQVIA1:
- Additional equipment needed depends upon which pump method is selected
- Make sure, where necessary, the equipment being selected is compatible with each other (eg, ensure syringes are compatible with syringe driver pump, and ensure pump tubing is compatible with peristaltic infusion pump and offers flow rates up to 300 mL/h/site)
- HYQVIA [prescribing information]. Lexington, MA: Baxalta US Inc.
- Food and Drug Administration. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-efficacy-and-pharmacokinetic-studies-support-marketing-immune-globulin-intravenous-human. Accessed May 28, 2019.
- Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-440.
- Data on file. Takeda US Inc. 2019.